INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 435m ago
HOUSE PTR35m ago
SEC 13F35m ago
ROBINHOOD CHAIN35m ago
SEC FORM 4/Option exerciseVerified dataRule 10b5-1 plan

Olsson Shawn reported LENZ

Chief Commercial Officer · LENZ Therapeutics, Inc. · Common Stock

Side
M
Value
$21K
Shares
10.0K
Price
$2.08
Executed
Nov 17, 2025
Disclosed
Nov 19, 2025
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Nov 17 executedNov 19, 2025 disclosed

LENZ · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
11/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+13 / 25

$21K reported value · 211.3% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · LENZ

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    50
    CR
    Chevallard Daniel R.Chief Financial Officer
    LENZLENZ Therapeutics, Inc.
    Open-market purchase
    		BUY$64K
    7,500 sh
    		Mar 27, 2026Mar 30, 2026
    traded Mar 27, 2026
    		+3dSEC FORM 4

    Evidence

    57
    SB
    Schimmelpennink Evert B.Director, President, CEO and Secretary
    LENZLENZ Therapeutics, Inc.
    Open-market purchase
    		BUY$251K
    28.1K sh
    		Mar 27, 2026Mar 30, 2026
    traded Mar 27, 2026
    		+3dSEC FORM 4

    Evidence

    51
    GP
    George Jeffrey P.Director
    LENZLENZ Therapeutics, Inc.
    Open-market purchase
    		BUY$50K
    5,592 sh
    		Mar 27, 2026Mar 30, 2026
    traded Mar 27, 2026
    		+3dSEC FORM 4

    Evidence

    5
    OS
    Olsson ShawnChief Commercial Officer
    LENZLENZ Therapeutics, Inc.
    Grant or award
    		A—
    14.0K sh
    		Jan 2, 2026Jan 6, 2026
    traded Jan 2, 2026
    		+4dSEC FORM 4

    Evidence

    9
    OM
    Odrich MarcChief Medical Officer
    LENZLENZ Therapeutics, Inc.
    Grant or award
    		A—
    84.2K sh
    		Jan 2, 2026Jan 6, 2026
    traded Jan 2, 2026
    		+4dSEC FORM 4

    Evidence

    9
    OM
    Odrich MarcChief Medical Officer
    LENZLENZ Therapeutics, Inc.
    Grant or award
    		A—
    14.0K sh
    		Jan 2, 2026Jan 6, 2026
    traded Jan 2, 2026
    		+4dSEC FORM 4

    Evidence

    5
    OS
    Olsson ShawnChief Commercial Officer
    LENZLENZ Therapeutics, Inc.
    Grant or award
    		A—
    84.2K sh
    		Jan 2, 2026Jan 6, 2026
    traded Jan 2, 2026
    		+4dSEC FORM 4

    Evidence

    7
    OS
    Olsson ShawnChief Commercial Officer
    LENZLENZ Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    10.0K sh
    		Nov 17, 2025Nov 19, 2025
    traded Nov 17, 2025
    		+2dSEC FORM 4

    Evidence

    20
    OS
    Olsson ShawnChief Commercial Officer
    LENZLENZ Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$153K
    5,788 sh
    		Nov 17, 2025Nov 19, 2025
    traded Nov 17, 2025
    		+2dSEC FORM 4

    Evidence

    16
    OS
    Olsson ShawnChief Commercial Officer
    LENZLENZ Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$108K
    4,212 sh
    		Nov 17, 2025Nov 19, 2025
    traded Nov 17, 2025
    		+2dSEC FORM 4

    Evidence

    49
    MW
    Mccollum James WDirector
    LENZLENZ Therapeutics, Inc.
    Open-market purchase
    		BUY$239K
    10.5K sh
    		Nov 7, 2025Nov 10, 2025
    traded Nov 7, 2025
    		+3dSEC FORM 4

    Evidence

    46
    CR
    Chevallard Daniel R.Chief Financial Officer
    LENZLENZ Therapeutics, Inc.
    Open-market purchase
    		BUY$50K
    2,178 sh
    		Nov 7, 2025Nov 7, 2025
    traded Nov 7, 2025
    		+0dSEC FORM 4

    Evidence

    34
    CR
    Chevallard Daniel R.Chief Financial Officer
    LENZLENZ Therapeutics, Inc.
    Open-market purchase
    		BUY$454
    20 sh
    		Nov 7, 2025Nov 7, 2025
    traded Nov 7, 2025
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002015796-25-000003
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Nov 17, 2025
    Published
    Nov 19, 2025
    Ingested by INSIDER
    Nov 5, 04:32 UTC
    Last re-read
    Nov 5, 04:32 UTC

    Extracted facts

    Filer
    Olsson Shawn
    Role
    Chief Commercial Officer
    Transaction
    Option exerciseAs filed: “M”
    Asset
    LENZ Therapeutics, Inc.
    Ticker
    LENZ
    Shares
    10.0K
    Price per share
    $2.08
    Value
    $20,800
    Execution date (reported)
    Nov 17, 2025
    Owned after transaction
    14.7K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 10.0K
    • Price: $2.08

    = $20,800

    What this establishes

    Olsson Shawn filed this Form 4 reporting a option exercise of LENZ on Nov 17, 2025. It became public on Nov 19, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Commercial Officer
    Olsson Shawncik:0002015796
    Issuer
    LENZ Therapeutics, Inc.cik:0001815776

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.